SRRK Stock — Scholar Rock Holding Corporation

Scholar Rock Holding Corporation (SRRK)

Updated October 16, 2026.

SRRK is a Stock. Total return is 157.4% over the past 8.4 years, 60.8 points behind SPY at 218.2%.

Scholar Rock Holding Corporation is a biopharmaceutical company developing monoclonal antibody treatments for rare neuromuscular diseases, including spinal muscular atrophy and facioscapulohumeral muscular dystrophy, with its lead candidate Apitegromab currently in Phase 2 clinical trials. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage biotechnology development with a focus on rare disease treatments.

SRRK performance versus SPY

Price and return data through 2026-10-16.

Total return is 157.4% over the past 8.4 years, 60.8 points behind SPY at 218.2%. Over the past year its total return — price change plus distributions reinvested — is 35.5%. Its deepest 1-year drawdown was 34.0%.

SRRK key facts

Asset type

Stock

Asset class

Equity

Inception date

05/24/2018

Distribution frequency

None

Last close

$39.90 (as of 2026-10-16)

Market cap

$4,859,232,752

Average volume

2893997.0

Beta

0.623

Payout ratio

0.0%

EPS

$-3.32

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

SRRK risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 34.0%.

Who may consider SRRK — and who may not

It is a weaker fit for investors who need monthly cash flow (SRRK does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on SRRK

• All tickers starting with S

Tagged: Healthcare.

Frequently asked questions